Association of MALAT1 expression in gastric carcinoma and its clinicopathological features significances in an Iranian patient Association of long non-coding RNAs MALAT1 and gastric cancer
Gastroenterology and Hepatology from Bed to Bench,
8 March 2021
The aim of this study was to evaluate the expression of MALAT1 and the relationship between their expressions with clinical characteristics in an Iranian gastric cancer patient.
Long non-coding RNAs (LncRNAs) play critical roles in the initiation and development of gastric cancer. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved lncRNA and plays important roles in various types of human cancer. However, our understanding about the role of lncRNAs in the occurrence and development of gastric cancer are not fully clear.
Materials and Methods
This cross-sectional study was performed on 41 gastric tumor tissue samples with matched normal adjacent tumor tissues. The RNA level of lncRNA MALAT1 gene were assessed using the quantitative Real-time polymerase chain reaction. B2M was used as an internal control. The 2 -ΔΔCq method was used to determine the expression fold changes.
A significant association was observed between the levels of MALAT1, gene in gastric tumor tissues comparing normal adjacent tissues (Mean = 1.558, p= 0.014). In addition, clinicopathologic data comparing with MALAT1 RNA expression levels in gastric cancer tissues was evaluated. However, no significant association were observed between the relative expression of MALAT1 and the stage, grad, H. pylori infection and tumor size groups among gastric cancer patients (P= 0.82, p= 0.904, p=0.407 and p= 0.701, respectively).
Our results showed that MALAT1 have a significant association in gastric cancer. The expression of MALAT1 may be used as a diagnostic biomarker for monitoring gastric cancer patients.
Keywords: Gastric Cancer, MALAT1, LncRNA, Clinicopathological Feature
- Gastric Cancer, MALAT1, LncRNA, Clinicopathological Feature
2. La Vecchia C, Conte P. Cancer Control in Central and Eastern Europe. The oncologist. 2016;21(10):1161-2.
3. Riquelme I, Ili C, Roa JC, Brebi P. Long non-coding RNAs in gastric cancer: mechanisms and potential applications. Oncotarget. 2016.
4. Poursheikhani A, Bahmanpour Z, Razmara E, Mashouri L, Taheri M, Morshedi Rad D, et al. Non-coding RNAs underlying chemoresistance in gastric cancer. Cellular oncology (Dordrecht). 2020.
5. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WPJCm, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. 2018;10:239.
6. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya TJCs. Emerging roles of long non‐coding RNA in cancer. 2018;109(7):2093-100.
7. Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Molecular cancer. 2020;19(1):96.
8. Chaudhary R, Lal A. Long noncoding RNAs in the p53 network. Wiley Interdiscip Rev RNA. 2016.
9. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut. 2020;69(4):748-63.
10. Ghafouri-Fard S, Taheri M. Long non-coding RNA signature in gastric cancer. Experimental and molecular pathology. 2020;113:104365.
11. Tan H, Zhang S, Zhang J, Zhu L, Chen Y, Yang H, et al. Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications. Theranostics. 2020;10(19):8880-902.
12. Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Molecular cancer. 2020;19(1):62.
13. Chen Q, Zhu C, Jin Y. The Oncogenic and Tumor Suppressive Functions of the Long Noncoding RNA MALAT1: An Emerging Controversy. Front Genet. 2020;11:93.
14. Wang W, Zhu Y, Li S, Chen X, Jiang G, Shen Z, et al. Long noncoding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting β-catenin via Ezh2. Oncotarget. 2016;7(18):25668-82.
15. Guo F, Guo L, Li Y, Zhou Q, Li Z. MALAT1 is an oncogenic long non-coding RNA associated with tumor invasion in non-small cell lung cancer regulated by DNA methylation. International journal of clinical and experimental pathology. 2015;8(12):15903-10.
16. Zhang YF, Li CS, Zhou Y, Lu XH. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer. Life Sci. 2020;244:117280.
17. Chaleshi V, Iran S, Alebouyeh M, Mirfakhraie R, Aghdaei HAJG, Bench HfBt. Evaluation of MALAT1 promoter DNA methylation patterns in early colorectal lesions and tumors. 2019;12(Suppl1):S58.
18. Chaleshi V, Irani S, Alebouyeh M, Mirfakhraie R, Asadzadeh Aghdaei H. Association of lncRNA‑p53 regulatory network (lincRNA‑p21, lincRNA‑ROR and MALAT1) and p53 with the clinicopathological features of colorectal primary lesions and tumors. Oncology Letters. 2020;19(6):3937-49.
19. Washington K. of the AJCC cancer staging manual: stomach. Annals of surgical oncology. 2010;17(12):3077-9.
20. Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020;18(3):534-42.
21. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess AJBg. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. 2007;8(1):39.
22. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin β 4 predict metastasis and survival in early-stage non-small cell lung cancer. 2003;22(39):8031-41.
23. Chen Y, Huang W, Sun W, Zheng B, Wang C, Luo Z, et al. LncRNA MALAT1 promotes cancer metastasis in osteosarcoma via activation of the PI3K-Akt signaling pathway. 2018;51(3):1313-26.
24. Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu XJOl. MALAT1: A long non‑coding RNA highly associated with human cancers. 2018;16(1):19-26.
25. Guo J, Ding Y, Yang H, Guo H, Zhou X, Chen XJE, et al. Aberrant expression of lncRNA MALAT1 modulates radioresistance in colorectal cancer in vitro via miR-101-3p sponging. 2020:104448.
26. Liu X, Huang G, Zhang J, Zhang L, Liang ZJPo. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis. 2020;15(10):e0240321.
27. Pa M, Naizaer G, Seyiti A, Kuerbang GJORFP, Therapeutics CC. Long noncoding RNA MALAT1 functions as a sponge of MiR-200c in ovarian cancer. 2020.
28. Zhao L, Lou G, Li A, Liu YJMmr. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR‑375 sponging. 2020;22(2):1449-57.
29. Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang ZJJon-o. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. 2015;121(1):101-8.
30. Li X, Zhao J, Zhang H, Cai J. Silencing of LncRNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 Inhibits the Proliferation and Promotes the Apoptosis of Gastric Cancer Cells Through Regulating microRNA-22-3p-Mediated ErbB3. Onco Targets Ther. 2020;13:559-71.
31. Sebastian A, Hum NR, Hudson BD, Loots GG. Cancer-Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer. Microarrays (Basel, Switzerland). 2015;4(4):503-19.
32. Wu L, Wang X, Guo Y. Long non-coding RNA MALAT1 is upregulated and involved in cell proliferation, migration and apoptosis in ovarian cancer. Experimental and therapeutic medicine. 2017;13(6):3055-60.
33. Li J, Gao J, Tian W, Li Y, Zhang J. Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297. Cancer cell international. 2017;17:44.
34. Zheng H-T, Shi D-B, Wang Y-W, Li X-X, Xu Y, Tripathi P, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. 2014;7(6):3174.
35. Okugawa Y, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. 2014;35(12):2731-9.
36. Lai M-c, Yang Z, Zhou L, Zhu Q-q, Xie H-y, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. 2012;29(3):1810-6.
37. Pang E-J, Yang R, Fu X-b, Liu Y-fJTB. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. 2015;36(4):2403-7.
38. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. 2014;32(6):2485-92.
39. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu FJMb. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. 2012;8(9):2289-94.
40. Han Y, Liu Y, Nie L, Gui Y, Cai ZJU. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder. 2013;81(1):209. e1-. e7.
41. Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie P, et al. The role of MALAT1 correlates with HPV in cervical cancer. 2014;7(6):2135-41.
42. Guo F, Li Y, Liu Y, Wang J, Li Y, Li GJABBS. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. 2010;42(3):224-9.
- Abstract Viewed: 0 times